
Maria Gerosa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/115575/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132, 1365-1371.	0.6	573
2	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. Arthritis and Rheumatism, 2012, 64, 1970-1977.	6.7	134
3	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 609-615.	0.5	132
4	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmunity Reviews, 2019, 18, 406-414.	2.5	106
5	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. Thrombosis and Haemostasis, 2014, 112, 727-735.	1.8	102
6	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106.	2.5	101
7	Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Research and Therapy, 2014, 16, 209.	1.6	99
8	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunologic Research, 2017, 65, 17-24.	1.3	97
9	Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β ₂ â€Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti–Domain 1 to Anti–Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome. Arthritis and Rheumatology, 2015, 67, 2196-2204.	2.9	94
10	Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Research and Therapy, 2014, 16, R144.	1.6	88
11	Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?. Autoimmunity, 2005, 38, 39-45.	1.2	86
12	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. Journal of Autoimmunity, 2018, 86, 1-8.	3.0	86
13	P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus. Journal of Experimental Medicine, 2019, 216, 317-336.	4.2	83
14	Patients with antiphospholipid syndrome display endothelial perturbation. Journal of Autoimmunity, 2010, 34, 105-110.	3.0	82
15	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. Blood, 2016, 127, 365-367.	0.6	67
16	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. Thrombosis and Haemostasis, 2018, 47, 639-646.	1.8	62
17	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. Journal of Autoimmunity, 2018, 90, 1-27.	3.0	60
18	Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. Journal of Autoimmunity, 2018, 90, 76-83.	3.0	60

MARIA GEROSA

#	Article	IF	CITATIONS
19	New Tests to Detect Antiphospholipid Antibodies: Anti-DomainÂl Beta-2-Glycoprotein-I Antibodies. Current Rheumatology Reports, 2014, 16, 402.	2.1	59
20	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‣ife Setting. Arthritis and Rheumatology, 2020, 72, 1314-1324.	2.9	58
21	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. Rheumatology, 2020, 59, 1306-1314.	0.9	53
22	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. Seminars in Arthritis and Rheumatism, 2020, 50, 1150-1157.	1.6	52
23	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. Journal of Rheumatology, 2017, 44, 1165-1172.	1.0	51
24	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. Frontiers in Immunology, 2018, 9, 1388.	2.2	51
25	Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmunity Reviews, 2015, 14, 686-691.	2.5	46
26	Cardiac Involvement in Systemic Autoimmune Diseases. Clinical Reviews in Allergy and Immunology, 2002, 23, 247-262.	2.9	45
27	Endothelium as a target for antiphospholipid antibodies. Immunobiology, 2003, 207, 29-36.	0.8	45
28	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmunity Reviews, 2019, 18, 164-176.	2.5	44
29	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. Rheumatology, 2021, 60, 1114-1124.	0.9	41
30	Are patients with systemic lupus erythematosus at increased risk for COVID-19?. Annals of the Rheumatic Diseases, 2021, 80, e25-e25.	0.5	41
31	Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Twoâ€year outcomes after the study closure. Journal of Thrombosis and Haemostasis, 2021, 19, 531-535.	1.9	40
32	The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Review of Clinical Pharmacology, 2018, 11, 987-998.	1.3	39
33	Characteristics of Patients With Antiphospholipid Antibody Positivity in the <scp>APS ACTION</scp> International Clinical Database and Repository. Arthritis Care and Research, 2022, 74, 324-335.	1.5	39
34	Updating on the Pathogenic Mechanisms 5 of the Antiphospholipid Antibodies-Associated Pregnancy Loss. Clinical Reviews in Allergy and Immunology, 2008, 34, 332-337.	2.9	38
35	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody–Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. Arthritis Care and Research, 2019, 71, 134-141.	1.5	37
36	Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?. Rheumatology, 2012, 51, 2186-2190.	0.9	35

Maria Gerosa

#	Article	IF	CITATIONS
37	Purified IgG from Patients with Obstetric but not IgG from Nonâ€obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion. American Journal of Reproductive Immunology, 2015, 73, 390-401.	1.2	35
38	β2 Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. Journal of Immunology, 2017, 198, 2640-2648.	0.4	34
39	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. Frontiers in Immunology, 2019, 10, 1948.	2.2	33
40	Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Frontiers in Immunology, 2016, 7, 5.	2.2	30
41	Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy, 2016, 17, 1539-1547.	0.9	28
42	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 773.	2.2	28
43	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus, 2020, 29, 1353-1363.	0.8	28
44	Transforming growth factor β1 in the pathogenesis of autoimmune congenital complete heart block: Lesson from twins and triplets discordant for the disease. Arthritis and Rheumatism, 2006, 54, 356-359.	6.7	25
45	Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Review of Clinical Immunology, 2014, 10, 1505-1517.	1.3	25
46	"Disease knowledge index―and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine, 2019, 86, 475-481.	0.8	25
47	Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opinion on Drug Safety, 2014, 13, 1591-1599.	1.0	24
48	Recognition and management of antiphospholipid syndrome. Current Opinion in Rheumatology, 2016, 28, 51-59.	2.0	23
49	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort. Journal of Autoimmunity, 2021, 124, 102729.	3.0	23
50	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
51	Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. Clinical and Experimental Rheumatology, 2015, 33, 688-93.	0.4	18
52	Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series. Clinical and Experimental Rheumatology, 2018, 36, 643-647.	0.4	18
53	Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some) Tj ETQq1	1.0.7843 1.0	14 rgBT /0 17
54	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. Biomedicines, 2021, 9, 671.	1.4	17

MARIA GEROSA

#	Article	IF	CITATIONS
55	Epigenetics, pregnancy and autoimmune rheumatic diseases. Autoimmunity Reviews, 2020, 19, 102685.	2.5	16
56	Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. Rheumatology, 2022, 61, 1928-1935.	0.9	15
57	Congenital Fetal Heart Block: a Potential Therapeutic Role for Intravenous Immunoglobulin. Obstetrics and Gynecology, 2011, 117, 177.	1.2	14
58	Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year. Clinical Immunology, 2021, 231, 108845.	1.4	14
59	Antiâ€phospholipid antibodies and reproductive failures. American Journal of Reproductive Immunology, 2021, 85, e13258.	1.2	13
60	Obstetric Antiphospholipid Syndrome: Lobsters Only? Or Should We Also Look for Selected Red Herrings?. Journal of Rheumatology, 2015, 42, 158-160.	1.0	12
61	Lung Disease in Antiphospholipid Syndrome. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 278-294.	0.8	10
62	Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis. Swiss Medical Weekly, 2016, 146, w14394.	0.8	9
63	Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases. Frontiers in Pharmacology, 2022, 13, 841785.	1.6	9
64	Circulating stem cell factor in patients with chronic idiopathic urticaria. Annals of Allergy, Asthma and Immunology, 2003, 91, 79-81.	0.5	8
65	Diversity and somatic hypermutation of the Ig VHDJH, VκJκ, and VλJλ Gene Segments in Lymphoma B cells: Relevance to the origin of the neoplastic B cell clone. Human Immunology, 2003, 64, 69-81.	1.2	7
66	Pregnancy in juvenile idiopathic arthritis: maternal and foetal outcome, and impact on disease activity. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210803.	1.2	4
67	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. Clinical Reviews in Allergy and Immunology, 2022, 62, 346-353.	2.9	2
68	Non-organ Specific Autoimmunity Involvement in Cardiovascular Disease. Handbook of Systemic Autoimmune Diseases, 2003, 1, 41-51.	0.1	1
69	Update on Pregnancy in Autoimmune Diseases. Women's Health, 2007, 3, 417-420.	0.7	1
70	Autoantibodies – Future Trends. , 2014, , 825-828.		1
71	FRI0199â€EFFECTIVENESS AND SAFETY OF BELIMUMAB IN PATIENTSWITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC STUDY. , 2019, , .		1
72	Myocardial involvement in anti-phospholipid syndrome: Beyond acute myocardial infarction.	2.5	1

2.51

Autoimmunity Reviews, 2022, 21, 102990.

MARIA GEROSA

#	Article	IF	CITATIONS
73	Psychosocial burden in young patients with primary anti-phospholipid syndrome: an Italian nationwide survey (The AQUEOUS study). Clinical and Experimental Rheumatology, 2021, 39, 938-946.	0.4	1
74	5th International Conference on Sex Hormones, Pregnancy and Rheumatic Disease. Future Rheumatology, 2007, 2, 251-255.	0.2	0
75	INTERFERON-INDUCIBLE PROTEIN IFI16 AUTOANTIBODIES. , 2007, , 331-337.		0
76	Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome. Current Rheumatology Reviews, 2010, 6, 18-24.	0.4	0
77	Cardiovascular Issues in SLE. Rare Diseases of the Immune System, 2016, , 133-145.	0.1	0
78	FRI0569â€WHAT DOES IT MEAN TO BECOME PREGNANT WITH JUVENILE IDIOPATHIC ARTHRITIS? A MONOCENTRIC EXPERIENCE IN A TERTIARY CENTRE OF MILAN DEDICATED TO YOUNG ADULTS AFFECTED BY JIA. , 2019, , .		0
79	Editorial: New Therapies in the Field of Rheumatology. Frontiers in Pharmacology, 2020, 10, 1604.	1.6	0
80	Ultrasound assessment of lacrimal glands: a cross-sectional study in healthy subjects and a preliminary study in primary Sjögren's syndrome patients. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 203-209.	0.4	0
81	Clinical Delphi on aPL Negativization: Report from the APS Study Group of the Italian Society for Rheumatology (SIR-APS). Thrombosis and Haemostasis, 2022, 122, 1612-1620.	1.8	Ο